SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin eyes Rs 780 cr from US market by FY14

28 Nov 2011 Evaluate

Drug firm Lupin is expecting revenues of up to $150 million (over Rs 780 crore) from its oral contraceptive (OC) segment in the US market by 2013-14, a segment in which it had forayed recently. The firm entered into the OC segment in the US in September this year with the US health regulator approving its generic norethindrone tablets in the strength of 0.35 mg. The company is looking at around $125 million to $150 million from the oral contraceptive market in the US by 2013-14, when its portfolio would be at its peak.

Since its foray, the company has received two more approvals from the US Food and Drug Administration (USFDA) in the OC segment, taking the total approvals to three in the US market. Apart from generic norethindrone tablets, the company has received approvals from the USFDA to market generic versions of LoSeasonique tablets and Femcon Fe respectively. The company's OC segment pipeline consists of 30 filings to the USFDA till date, of which it has already received approval for three generic drugs. According to industry estimates, the US market for oral contraceptives is pegged to be around $4.5 billion.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×